OmniAb (OABI) Net Income towards Common Stockholders (QoQ) (2021 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | OmniAb | 334.72 Mn | 291.75 Mn | 14.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45.64% |
| Dec 31, 2025 | 14.20% |
| Sep 30, 2025 | -4.09% |
| Jun 30, 2025 | 12.77% |
| Mar 31, 2025 | -39.27% |
| Dec 31, 2024 | 20.19% |
| Sep 30, 2024 | -20.12% |
| Jun 30, 2024 | 28.11% |
| Mar 31, 2024 | -34.92% |
| Dec 31, 2023 | 10.71% |
| Sep 30, 2023 | -6.86% |
| Jun 30, 2023 | -141.44% |
| Mar 31, 2023 | -189.44% |
| Dec 31, 2022 | 1,482.57% |
| Sep 30, 2022 | 62.05% |
| Jun 30, 2022 | 64.57% |
| Mar 31, 2022 | -1,419.46% |
| Dec 31, 2021 | -362.71% |
| Sep 30, 2021 | -2,288.33% |
| Jun 30, 2021 | 71.94% |